IMM 5.26% 30.0¢ immutep limited

2 cent party, page-33

  1. 7,495 Posts.
    lightbulb Created with Sketch. 74

    Hodgie28,

    I think you raised a valid question which should be forwarded to management for their response !


    As for me, I am taking this opportunity doubling up my holding. I followed Altium with all my saving in the stock today mate. My  holding of IMM is now exceeding 5M.  I do have some skins in the game and put my money where my mouth is atm.


    The intentions of both parties are clearly stated below as extracted from the recent announcement. I’m very comfortable with that:


    (1) Immutep’s CEO, Marc Voigt, commented, “We are pleased to have Altium Capital lead this financing. Altium joins a growing number of specialist healthcare funds we have welcomed as investors in Immutep over the past year, as they recognize Immutep is leading the excitement around LAG-3. This financing, raised in a difficult market environment, has extended Immutep’s cash runway beyond the estimated AIPAC data readout in H2 2019, as well as potential meaningful data points from our ongoing and planned TACTI clinical studies.”

    they recognize Immutep is leading the excitement around LAG-3. This financing, raised in a difficult market environment, has extended Immutep’s cash runway beyond the estimated AIPAC data readout in H2 2019, as well as potential meaningful data points from our ongoing and planned TACTI clinical studies.”


    (2) Jacob Gottlieb, Altium Capital’s CEO, commented, “The potential therapeutic relevance of LAG-3 is becoming increasing appreciated within both the biopharma industry and the investment community. Immutep has already established itself as a clear leader in the understanding of the LAG-3 immune control mechanism, having built partnerships with five of the world’s largest pharmaceutical companies and operating under the research direction of Dr. Frederic Triebel.”“We are pleased to have the opportunity to support Immutep’s innovative clinical and preclinical product candidates. We have a particular interest in the potential of IMP761, its preclinical agonist antibody for autoimmune diseases. This investment is consistent with our fundamental long-term investment strategy,” Gottlieb concluded.


    Good luck to all holders


    Last edited by ML173: 20/12/18
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
0.015(5.26%)
Mkt cap ! $486.6M
Open High Low Value Volume
29.0¢ 30.8¢ 29.0¢ $833.7K 2.793M

Buyers (Bids)

No. Vol. Price($)
25 258479 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 221018 27
View Market Depth
Last trade - 15.13pm 22/11/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.